Clinical trial · Observational
Population Pharmacokinetics of Imatinib in CML Patients in Iran
NCT02146846CI-TRIAL-00023781terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Imatinib, CML
- description
- Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
- interventionNames
- Drug: Imatinib
Primary outcomes (1)
- measure
- Percent of changes of AUC, trough Concentration from predicted values
- timeFrame
- Blood sampling are collected on atleast the 30th day of treatment at the following time: 1 hour before the dose and 1 hour after the dose
- description
- The influence of patients' characteristic on the pharmacokinetics of Imatinib will be assessd.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patient in chronic phase of myeloid leukemia * no liver and renal failure Exclusion Criteria: * multiple dug treatment * previous treatment of interferon * patients in blast or accelerated phase
References
Publications (0)
Data not yet available
No reference posted for this study.